Media.Player

MOEVELENT ANTI-CD3 ADJUVANTS

Detailed Technology Description

None

Others

*Abstract

UNIVERSITY OF MISSOURIOffice of Technology Management and Industry RelationsNon-confidential Abstract of InventionUM Disclosure Number: 18UMC056Title: Monovalent Anti-CD3 Adjuvants to Increase Immunotherapeutic EfficacyInnovation: Inventors at the University of Missouri have developed a monovalent anti-CD3 antibody for use as an adjuvant to increase the immune response produced against an antigen, for example tumor associated antigens. These antibodies can also be used in immunotherapy alone, or in combination with existing therapies, and in vaccine compositions to amplify the immune response produced against an exogenously introduced antigen.Background: Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases reported in 2012, a number that is expected to rise by about 70% over the next 2 decades. It is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015. The total annual economic cost of cancer in 2010 was estimated at approximately US$ 1.16 trillion.A variety of therapeutic approaches are currently used in the battle against cancer, with immunotherapy a relatively recent focus of drug companies and clinicians. Patient response to immunotherapy has been mixed, with patients generally responding either poorly or very well. One reason for a poor response could be failure to evoke an immune response to weak tumor antigens. The current invention has been demonstrated to strengthen the immune response to weak antigens, while not interfering with response to strong antigens, and therefore presents a novel new tool for cancer treatment and potentially other immunotherapies.Applications: Can be used as alone or as an adjuvant to other immunotherapy drugs: monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immune-modulators.Advantages: - This monovalent anti-CD3 adjuvant selectively acts to enhance physiologic T cell responses to weak antigens without stimulating antigen-unengaged T cells and without interrupting T cell responses to strong antigens.- Reduced risk of adverse immune responsesPatent status: Patent pendingInventors:- Diana Gil Pages- Adam G SchrumFor more information contact:Brian Buntaine, Sr. Licensing & Business Development AssociateOffice of Technology Management and Industry RelationsEmail: buntaineb@missouri.eduPhone: 573-882-0470

*Principal Investigator

Name: Diana Gil Pages, Associate Professor

Department:

Name: Adam Schrum, Associate Professor

Department:

Country/Region

USA